+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study



Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study



European Heart Journal 35(5): 290-298



To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). Six thousand five hundred and ninety-five participants aged 45-54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054166621

Download citation: RISBibTeXText

PMID: 23839541

DOI: 10.1093/eurheartj/eht232


Related references

Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Cardiovascular Drugs and Therapy 29(2): 187-197, 2016

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circulation. Cardiovascular Quality and Outcomes 11(4): E004171, 2018

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA 314(2): 142-150, 2015

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation 136(12): 1087-1098, 2017

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 342: D1672, 2011

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. American Journal of Medicine 114(6): 485-494, April 15, 2003

Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clinical Therapeutics 31(12): 2919-30; Discussion 2916-8, 2010

Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. European Journal of Clinical Pharmacology 67(4): 407-414, 2011

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 117(22): 2875-2883, 2008

Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Irish Medical Journal 99(5): 144-145, 2006

Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124(2): 146-153, 2011

Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Advances in Therapy 35(12): 2214-2223, 2018

Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland. Value in Health 18(6): 896-905, 2016

Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. Bmc Research Notes 5: 373, 2013

Cost-effectiveness of lipid-lowering treatment for the primary and secondary prevention of cardiovascular disease A population-based analysis. Canadian Journal of Cardiology 16(Suppl. F): 165F, 2000